FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval
WASHINGTON — Acting Food and Drug Administration Commissioner Janet Woodcock acknowledged on Wednesday her agency may have misstepped in its handling of its controversial approval of a new Alzheimer’s drug.
She was emphatic in her defense of the therapy and the agency’s approval decision in an interview at STAT’s Breakthrough Summit, but said, “it’s possible that the process could have been handled in a way that would have decreased the amount of controversy involved.”
